CN100496609C - Stable liposome composition - Google Patents
Stable liposome composition Download PDFInfo
- Publication number
- CN100496609C CN100496609C CNB2006101487072A CN200610148707A CN100496609C CN 100496609 C CN100496609 C CN 100496609C CN B2006101487072 A CNB2006101487072 A CN B2006101487072A CN 200610148707 A CN200610148707 A CN 200610148707A CN 100496609 C CN100496609 C CN 100496609C
- Authority
- CN
- China
- Prior art keywords
- liposome
- cholesterol
- paclitaxel
- phospholipid
- hydrogenation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 75
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 75
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 75
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 66
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 34
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 29
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims abstract description 28
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims abstract description 27
- 229930006000 Sucrose Natural products 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 14
- 239000011734 sodium Substances 0.000 claims abstract description 14
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 10
- 239000011591 potassium Substances 0.000 claims abstract description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 34
- 238000005984 hydrogenation reaction Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 9
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 235000021003 saturated fats Nutrition 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 208000011645 metastatic carcinoma Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 14
- 238000004108 freeze drying Methods 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 4
- 239000010409 thin film Substances 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
- 239000010408 film Substances 0.000 description 18
- 239000008215 water for injection Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 9
- 244000068988 Glycine max Species 0.000 description 9
- 235000010469 Glycine max Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229930003427 Vitamin E Natural products 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- -1 polyoxyethylene Polymers 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001132 ultrasonic dispersion Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000013557 residual solvent Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229920006289 polycarbonate film Polymers 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 150000001841 cholesterols Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052756 noble gas Inorganic materials 0.000 description 3
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 3
- 229940108949 paclitaxel injection Drugs 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- KPBYZDRYGZZKIG-UHFFFAOYSA-N [hexadecanoyloxy(hydroxy)phosphoryl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OP(O)(=O)OC(=O)CCCCCCCCCCCCCCC KPBYZDRYGZZKIG-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- PMRVNBLFPMPZHZ-WHDSNZPESA-N (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 PMRVNBLFPMPZHZ-WHDSNZPESA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- IBDXZWQCLMSDKQ-FDXOKOSPSA-N i-cholesterol Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CCCC(C)C)[C@@H](O)[C@@]31[C@H]2C3 IBDXZWQCLMSDKQ-FDXOKOSPSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011553 magnetic fluid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A stable liposome composition used as the carrier of anticancer taxol is prepared from saturated hydrogenated phosphate, cholesterol, sodium (or potassium) cholesterol sulfate and cane sugar through thin-film evaporating-freeze-drying process.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of stable liposome composition, and application and the preparation method of this liposome composition aspect envelope paclitaxel, and the purposes of this Paclitaxel liposome.
Background technology
Anti-cancer medicine paclitaxel (paclitaxe) is the natural product that extracts from the bark of yewtree (Taxus brevifolia Nutt.), is used for the treatment of ovarian cancer, breast carcinoma and nonsmall-cell lung cancer.But atomic, only solvable in organic solvents such as methanol, ethanol, dimethyl sulfoxide because of its dissolubility in water, thereby bring very big difficulty for the paclitaxel intravenously administrable.Solve one of its deliquescent known method, be to adopt surfactant polyoxyethylene Oleum Ricini and ethanol as the dissolution with solvents paclitaxel, paclitaxel injection (U.S. Bristol-Myers Squibb Co. production as FDA (Food and Drug Adminstration) (FDA) in 1992 approval, commodity are called Taxol, at the commodity of China's registration taxol by name).Though polyoxyethylene castor oil can increase the water solublity of paclitaxel, can discharge histamine during owing to its degradation in vivo, thereby the serious quick reaction that surpasses may take place.In addition, paclitaxel itself also has haematics toxicity, bone marrow depression, leukopenia, thrombocytopenia, anemia and other toxicity.
Therefore, we expect to prepare a kind of stable preparation that can reduce the paclitaxel toxic and side effects, avoid on the one hand the anaphylaxis that brought by polyoxyethylene castor oil and ethanol double solvent, reduce the system toxicity of paclitaxel on the one hand.
Liposome (liposome) be can yet be regarded as the carrier of paclitaxel administration reach a kind of method of this purpose.The filmogen that liposome is commonly used has amphiphilic species such as phospholipid, cholesterol, sphingomyelins class, and wherein phospholipid is usually as the main composition composition of bimolecular lipid membrane, and cholesterol plays an important role to flowability, the pliability of adjusting film.
The basic research of the Paclitaxel liposome that just carries out since nineteen ninety generation shows that Paclitaxel liposome preparation is compared with injection, and curative effect is similar, but toxicity reduces, and toleration improves.At present in the Paclitaxel liposome research field, a plurality of disclosed technical schemes are arranged, as Sharma-A at " Int-J-Cancer " 1997,71, the Paclitaxel liposome that report is made with three kinds of synthetic phospholipids among the 103-107, the cationic-liposome of mentioning among the CN1378443A, the taxol nano magnetic target preparation of the ultra-fine magnetic fluid preparation of the employing of mentioning among the CN1399958A, the charged Paclitaxel liposome of mentioning among the W09513053 with phosphatidyl glycerol ester (PG) preparation, WO9318751, US5424073, US5648090, CN1275076A, mention among the CN1714094A with special phospholipid--the liposome of cuorin (cardiolipid) preparation, that mentions among the CN1291474A contains amino acid whose Paclitaxel liposome, the taxol hidden liposome of mentioning among the CN1391891A with the film preparation of amphipathic ethylene glycol-DSPE (PEG-DSPE) modified liposome.
Produce (the accurate word H20030357 of traditional Chinese medicines at the injection Paclitaxel liposome that China has gone on the market by Nanjing Sike Pharmaceutical Co., Ltd, commodity power by name is pounced on element), claim according to its description, still there is the risk that allergy takes place, need inject dexamethasone etc. in advance and carry out the antianaphylaxis pretreatment, compare with paclitaxel injection, aspect toleration, there is no obvious improvement.
In above-mentioned these technical schemes of mentioning, the not use of clear and definite saturated phospholipid.And as known in those skilled in the art, contain undersaturated fatty acid-based in matrix material commonly used such as natural phosphatidyl choline, the phospholipid of natural soybean, easily oxydrolysis becomes peroxide, malonaldehyde, fatty acid and lysophosphatide, and the latter can further be hydrolyzed into phosphoglycerol complex and fatty acid etc.The oxydrolysis of phospholipid also can make the flowability of film reduce, and promotes drug leakage.These unstable factors are unfavorable for preparation, storage and the safe handling clinically of liposome product.In addition, the compatibility of charged liposome and serum or blood, cell, tissue or the compatibility often can not expect, the large-scale aggregation that electrically forms in blood as strong cation causes the formation of organic thrombus in vivo.Simultaneously, as known to those skilled in the art, electric charge can influence the stability of bimolecular film with expecting, the liposome that charged phospholipid forms increases the repulsive force between the lipid somatocyst, make it to be difficult for coagulative precipitation, but simultaneously, the phospholipid of lotus like charges can cause the unstability of membrane structure in the bimolecular film, and therefore too high electric charge is not always useful to the stable entrapped drug of liposome.In addition, hidden liposome can make liposome stable, effectively prolong liposome circulation time in vivo, but it adopts amphipathic ethylene glycol-DSPE
(PEG-DSPE) cost an arm and a leg.In addition, there is the problem of selling at exorbitant prices equally in this special matrix material of cuorin (cardiolipid).
In liposome, cholesterol is attached in the bimolecular film of phospholipid formation, can realize the stability and the suitable flowability and the pliability of film.Content of cholesterol all has appreciable impact to medicine clad ratio, particle diameter.The derivant of cholesterol is also through being commonly used for the preparation of liposome.Be used to mix with preparation pH sensitive lipid body as the Cholesteryl hemisuccinate of mentioning among the US4891208 with PHOSPHATIDYL ETHANOLAMINE.This liposome has negative charge completely, and the efficient that is absorbed by cell is very low.Disclosed amphoteric compound among the CN1492876A based on sterol skeleton, the 3-position of ring is replaced by the amphiprotic group of one or more isoelectric point, IPs between 4 to 9, according to the technical scheme of this patent disclosure, need complicated synthesis technique to produce this cholesterol derivative.Multiple factor affecting pH value in the body, but just as recognized by those skilled in the art, the release of controlling medicine based on pH value in the body is always not reliable.
Therefore, if can prepare stabilized liposomes with the common widely matrix material in source, thereby control simultaneously its carrying capacity make its in vivo process more can expect, to be expected to remedy the deficiency of the above-mentioned technical scheme of mentioning, provide a kind of novel, stay-in-grade, be suitable for industrialized pharmaceutical carrier.
Summary of the invention
The invention provides a kind of liposome composition, described liposome does not adopt special charged phospholipid, also avoid using expensive Polyethylene Glycol-DSPE (PEG-DSPE) and cuorin (cardiolipid), and adopt the sodium salt of common hydrogenation saturated phospholipid, cholesterol, cholesterol sulfate or potassium salt as main carrier, the coating active composition, gained liposome composition carrying capacity of the present invention is low, quality is highly stable, possess industrial prospect, remedied the deficiency of existing liposome technology.
The present invention also provides a kind of preparation method of liposome composition, is that employing thin film evaporation-cryodesiccated method has obtained stable liposome composition.
The present invention also provides a kind of method that improves liposome stability and drug encapsulation stability simultaneously, promptly, the zeta current potential of liposome dispersion is remained in the scope of-15 to-35 millivolts (mV) near the sodium salt or the potassium salt that add micro-cholesterol sulfate in the neutral film forming matrix material.
The present invention especially provides a kind of stable Paclitaxel liposome composition and method of making the same, with and in the application of preparation aspect the antitumor drug.
The present invention forms and achieves the above object by optimizing liposome.One of essential component of preparation liposome of the present invention is the hydrogenation saturated phospholipid.Usually, the carbon number of the saturated fat acidic group that contains of this saturated phospholipid is 14～18.Carbon number is less than 14, and the ability of water reduced in liposome held, and after giving, the stability of liposome in blood reduces.On the other hand, carbon number is too much, and biocompatibility reduces, and because its carbochain increases, and phase transition temperature raises, producing in the liposome process needs very high temperature, and this stability to medicine and liposome all is adverse factors.Therefore, saturated phospholipid used in the present invention for example is selected from: soybean phospholipid that hydrogenation is saturated or lecithin, dipalmitoyl-phosphate ester choline, distearoyl phosphatidylcholine.The saturated phospholipid that the present invention uses is not limited to above phospholipid kind, and the carbon number of all saturated fat acidic groups that contains is 14～18 phospholipid, all is applicable to purpose of the present invention.
The preferred saturated phospholipid of the present invention is selected from the saturated soybean phospholipid of hydrogenation, saturated lecithin, dipalmitoyl-phosphate ester choline, the distearoyl phosphatidylcholine of hydrogenation, the more preferably saturated saturated lecithin of soybean phospholipid, hydrogenation of hydrogenation.The preferred purity of the saturated soybean phospholipid of hydrogenation is more than 97%, and its main component is a phosphatidylcholine, contains the phosphatidyl ethanolamine and the lipositol of trace simultaneously, because its aliphatic chain hydrogenation is saturated, thereby prevents hydrolysis oxidation.
Another of preparation liposome of the present invention must component be cholesterol.Cholesterol becomes membrane lipid, the flowability that can regulate bimolecular lipid membrane with the saturated phospholipid conduct.
The 3rd of preparation liposome of the present invention must component be 3 derivant of a class cholesterol, the sodium salt or the potassium salt of preferred cholesterol sulfate.The cholesterol sulfate sodium salt is a kind of amphiphilic species, and the amphotericin colloid dispersion (trade name AMPHOCIL) of U.S.'s listing promptly adopts it as matrix material, forms a kind of tabular dispersion with medicine.At US4822777, US5032582, US5194266 this compositions has been described.In the present invention, creatively with the sodium salt or the potassium salt of cholesterol sulfate, see the molecular structure shown in formula I and the formula II, be added in the above-mentioned matrix material micro-ly, obtain beyond thought effect, obtained the liposome that stable mean diameter is 100-300nm.
Formula I cholesterol sulfate sodium formula II cholesterol sulfate potassium
The sodium salt of cholesterol sulfate or potassium salt are a kind of amphiphilic species of bear electricity, its role is to: (1) joins in the membrane lipid micro-ly, can not influence the formation of film because of the repulsion between electric charge; (2) because the affinity interaction of its water-wet side and phospholipid water-wet side makes the bimolecular film of liposome more stable, increase the pliability of film, formed particle diameter and concentrate on the interior liposome of 100-300nm scope, simultaneously, reduced the leakage of medicine; (3) but there is not application risk in the derivant of this cholesterol safe disposal in vivo.
A technical scheme that realizes liposome of the present invention is as follows:
The one-tenth membrane lipid of liposome bilayer is made up of the material of following ratio: the molar ratio of hydrogenation saturated phospholipid, cholesterol, cholesterol sulfate sodium salt or potassium salt is: 100:20-50:0.2-5, more preferably the molar ratio of this three classes material is: 100:35-45:0.5-2, as active component, the molar ratio of itself and hydrogenation saturated phospholipid is: 2-8:100 with paclitaxel.In this scheme, also can further comprise natural type or synthesising complex E as antioxidant, the weight ratio of itself and hydrogenation saturated phospholipid is 0.3-1:100.Above-mentioned substance is prepared in proportion, can be obtained liposome of the present invention, for example adopt high pressure homogenize method, micropore squeezing and pressing method, ultrasonic dispersion, preferably adopt high pressure homogenize method with method for preparing lipidosome commonly used.The mean diameter of the liposome that the employing method for preparing obtains is in 100 nanometer to 300 nanometer range.Preparation method in the above-mentioned list of references of mentioning all is incorporated herein by reference.
Understand easily as those skilled in the art institute, liposome of the present invention not only can be used as the carrier of paclitaxel, is applicable to other taxanes material simultaneously, no matter and the size of its dissolubility in water.Equally, other cancer therapy drugs, as hydroxy camptothecin, too can liposome of the present invention as drug administration carrier.Other drug is no matter its water miscible difference under its cost performance acceptable prerequisite, can adopt liposome of the present invention as carrier equally.
The liposome that wherein contains reactive compound can be stablized with lyophilization, to make the suitable compositions form.In this process, need to add freeze drying protectant, rely on its stabilising membrane effect, guarantee the integrity of liposome.Known freeze drying protectant is a polyalcohols, as glycerol, glucose, sucrose, lactose, trehalose, aminoacid etc.In the present invention, preferably sucrose, lactose, maltose, glucose be as freeze-dried excipient, more preferably sucrose.According to the present invention, freeze drying protectant is 2 to 10 times of hydrogenation saturated phospholipid weight.
Drug-loaded liposome composition forms of the present invention can prepare by above-mentioned cryodesiccated method.For example, with active component, lipid material, if necessary, and antioxidant, be dissolved in proportion and become clear and bright solution in the The suitable solvent, under 50 ℃～65 ℃ constant temperature, according to conventional method, as the reduction vaporization method, if necessary, reduction vaporization in the presence of noble gas is removed the solvent in this liquid mixture, makes it film forming, add the aqueous solution that is dissolved with the freeze-dried excipient that calculates in proportion again, aquation, ultrasonic or homogenate to fineness is between 0.1～0.30 micron, with 0.22 micron filtering with microporous membrane degerming, divides in the suitable container such as the cillin bottle of packing into, remove from this mixture by lyophilization and to desolvate, obtain exsiccant pastille liposome, again packing container sealed or gland, seal with gland before can lead to noble gas.
In the preparation method of above-mentioned liposome, do not limit the amount of the employed solvent relevant, and the amount of the liquid of liposome dissolving is suited with lipid.Usually, The suitable solvent be nonpolar or low pole and can evaporate after do not stay the toxicity residue.According to conventional method,, be selected from methanol, ethanol, chloroform or their mixture as with regard to common employed organic solvent.In the present invention, preferred alcohol.The noble gas that adopts among the present invention is selected from nitrogen, helium, argon.Can steady in a long-termly store with the exsiccant pastille liposome membrane that this preparation method makes.
In the present invention, a preferred scheme is: active component is taxane and derivant thereof, more preferably paclitaxel.The present invention prepares the paclitaxel injecting and administering preparations of gained, and it does not contain Cremophor EL, has avoided containing the allergy that Cremophor EL causes, and compares with conventional paclitaxel injection, has improved toleration.
Gained Paclitaxel liposome of the present invention has been obtained useful effect:
(1) semi-finished product and stability of formulation
The Paclitaxel liposome compositions of the present invention preparation was measured its Zeta potential before lyophilizing, between-35mV-15mV, its Zeta potential is measured in room temperature placement 24 hours during this period, remains unchanged substantially.Liposome keeps suspended state in the compositions of suspendible, do not assemble.Redissolve the back according to measuring 24 hours with quadrat method, the gathering of liposome can not take place equally.The particle diameter and the later measurement result of redissolving show that its particle size distribution is at 100-250nm.And with same prescription but the liposome that does not contain the sulphuric acid cholesterol after placing two hours, sedimentation promptly takes place.
(2) effectiveness and the safety in utilization of treatment cancer
In animal experiment, Paclitaxel liposome administration group mice does not show toxicity, and every physical signs is normal, and waits dosage taxol treated animal of short duration stupor to occur after administration.Preliminary antitumor result of the test shows, liposome and the tumour inhibiting rate no difference of science of statistics that waits the dosage taxol.Hence one can see that, and Paclitaxel liposome of the present invention has improved the toleration of organism under the suitable situation of tumour inhibiting rate.
(3) probability of industrialization
Liposome composition of the present invention adopts saturated phospholipid and cholesterol as becoming membrane lipid, and these are commercial available pharmaceutical formulation material.Preparation technology of the present invention is simple, and step is few, and the preparation equipment of employing is a conventional equipment, is convenient to drop into suitability for industrialized production.As the liposome composition that active component makes, avoided containing the allergy that the formulation for paclitaxel of Cremophor EL causes with paclitaxel.According to the particle size distribution and the preliminary anxious malicious result of the test of redissolving the back Paclitaxel liposome, can analyze and learn after its intravenous injection to have the passive target characteristic, directional profile is in reticuloendothelial system, thereby the general toxicity of reduction paclitaxel has improved the toleration of patient's medication.
The Paclitaxel liposome compositions of gained of the present invention can be used for mammal with reasonable dosage safety ground in a suitable manner, can be used as mammal antineoplastic therapeutic agent, especially can be applicable to the treatment of human ovarian cancer, metastatic carcinoma of ovary, breast carcinoma, nonsmall-cell lung cancer, also can with the cisplatin combined treatment for cancer that is used for.
Below term used herein is specifically noted:
Term used herein " liposome " as those skilled in the known, refers to by having the closure folliculus that amphipathic phospholipid molecule and cholesterol are polymerized.In this article, refer in general sense unilamelar liposome.
Term used herein " one-tenth membrane lipid " refers to constitute the material of liposome bilayer, and what refer to phospholipid and cholesterol and cholesterol derivative in this article and constituted is overall, herein " bilayer material " with " become membrane lipid to have same implication.
Term used herein " saturated phospholipid " refers to that fatty acid-based in the phospholipid molecule is saturated, does not contain " C=C " two keys substantially in promptly fatty acid-based." hydrogenated phospholipid ", " hydrogenation saturated phospholipid " are same implications with this term in the literary composition.
Term used herein " particle diameter " is meant the mean diameter of the liposome that records with laser particle size determination instrument.
Term used herein " cholesterol sulfate sodium salt or potassium salt " is meant the chemical compound of structure shown in formula I and the formula II, with " the sulphuric acid cholesterol " mentioned in other documents, " cholesterol acyl sulfate ester " be same implication.
The present invention is further detailed explanation below in conjunction with embodiment, and the weight of the material that is obtained by the mol ratio conversion among the embodiment feeds intake, because phospholipid mostly is mixture, so get its about molecular weight when calculating.The molecular weight of the material that relates to is as follows:
Paclitaxel 860
The saturated soybean phospholipid 760 of hydrogenation
The saturated lecithin 780 of hydrogenation
Distearoyl phosphatidylcholine 760
Two Palmic acid phosphatidylcholines 740
Cholesterol 380
Cholesterol sulfate sodium 489
Cholesterol sulfate potassium 523
Embodiment provides as the purpose of illustration, does not constitute limitation of the scope of the invention.
Description of drawings:
The electromicroscopic photograph of the liposome that Fig. 1 embodiment 1 makes
The lipidosome freeze-dried preceding particle size distribution that Fig. 2 embodiment 1 makes
Particle size distribution after the liposome that Fig. 3 embodiment 1 makes redissolves
The preparation of embodiment 1 Paclitaxel liposome
Prescription:
Taxol 0.37g
Hydrogenated soya phosphatide 4g
Cholesterol 1g
Cholesterol sulfate sodium 0.05g
Vitamin E 0.055g
Sucrose 15g
Water for injection 120ml
Take by weighing respectively recipe quantity taxol, hydrogenated soya phosphatide, cholesterol, cholesterol sulfate sodium, support one's family Plain E adds the 100ml absolute ethyl alcohol, after the dissolving, under there is situation in nitrogen, drains solvent with Rotary Evaporators, The preparation film forming is put the placement of spending the night in the vacuum desiccator, removes residual solvent. Adding is with the water-soluble sugarcane of injection Sugar juice, 55 ℃ of water-baths, magnetic agitation 1 hour, the high pressure homogenizer homogeneous is used in ultrasonic dispersion, and 0.22 is little The aseptic filtration of rice pvdf membrane is distributed into cillin bottle, freeze drying. With the logical nitrogen of cillin bottle, gland seal.
According to method among 2005 editions two appendix XI X of the Chinese Pharmacopoeia E, the envelop rate that records sample is 93.0%.
According to method among 2005 editions two appendix XI X of the Chinese Pharmacopoeia E, measure lyophilizing proliposome sample with laser particle size determination instrument, its mean diameter is 138.6 nanometers, the mean diameter of water for injection redissolution sample is 178.5 nanometers.Its electromicroscopic photograph is seen Fig. 1, and particle size distribution figure sees Fig. 2 and Fig. 3.
The preparation of embodiment 2 Paclitaxel liposomes
Prescription:
Paclitaxel 0.09g
Hydrogenated soya phosphatide 4g
Cholesterol 0.4g
Cholesterol sulfate potassium 0.006g
Vitamin E 0.012g
Lactose 10g
Water for injection 150ml
The paclitaxel, hydrogenated soya phosphatide, cholesterol, cholesterol sulfate potassium, the vitamin E that take by weighing recipe quantity respectively add the 100ml dehydrated alcohol, after the dissolving, prepare film forming with Rotary Evaporators, put the placement of spending the night in the vacuum desiccator, remove residual solvent.Adding is with the dissolved sucrose solution of water for injection, 58 ℃ of water-baths, and magnetic agitation 1 hour, ultra-sonic dispersion adopts 0.8,0.4,0.2 micrometer polycarbonate film successively, extrudes with the extruder high pressure, divides the cillin bottle of packing into, lyophilization, gland seal.
Method is measured similarly to Example 1, and the mean diameter of sample is 164.6 nanometers before the lyophilizing, and envelop rate is 92.1%.
The preparation of embodiment 3 Paclitaxel liposomes
Prescription:
Paclitaxel 0.18g
Hydrogenated soya phosphatide 4g
Cholesterol 0.9g
Cholesterol sulfate sodium 0.13g
Vitamin E 0.04g
Sucrose 25g
Water for injection 150ml
The paclitaxel, hydrogenated soya phosphatide, cholesterol, cholesterol sulfate sodium, the vitamin E that take by weighing recipe quantity respectively add the 100ml dehydrated alcohol, after the dissolving, prepare film forming with Rotary Evaporators, put the placement of spending the night in the vacuum desiccator, remove residual solvent.Adding is with the dissolved sucrose solution of water for injection, 60 ℃ of water-baths, and magnetic agitation 1 hour, ultra-sonic dispersion is used the high pressure homogenizer homogenizing, extrudes with 0.2 micrometer polycarbonate film, and 0.22 micron pvdf membrane aseptic filtration divides the cillin bottle of packing into, lyophilization, gland seal.
Method is measured similarly to Example 1, and the mean diameter of sample is 152.6 nanometers before the lyophilizing, and envelop rate is 90.6%.
The preparation of embodiment 4 Paclitaxel liposomes
Prescription
Paclitaxel 0.2g
Hydrogenated soya phosphatide 4g
Cholesterol 0.7g
Cholesterol sulfate potassium 0.012g
Vitamin E 0.04g
Sucrose 15g
Water for injection 150ml
The paclitaxel, hydrogenated soya phosphatide, cholesterol, cholesterol sulfate potassium, the vitamin E that take by weighing recipe quantity respectively add the 100ml dehydrated alcohol, after the dissolving, prepare film forming with Rotary Evaporators, put the placement of spending the night in the vacuum desiccator, remove residual solvent.Adding is with the dissolved sucrose solution of water for injection, 50 ℃ of water-baths, and magnetic agitation 1 hour, ultra-sonic dispersion is used the high pressure homogenizer homogenizing, extrudes with 0.2 micrometer polycarbonate film, and 0.22 micron pvdf membrane aseptic filtration divides the cillin bottle of packing into, lyophilization, gland seal.
Method is measured similarly to Example 1, and the mean diameter of sample is 143.8 nanometers before the lyophilizing, and envelop rate is 88.2%.
The preparation of embodiment 5 Paclitaxel liposomes
Prescription
Paclitaxel 0.15g
Dipalmitoyl phosphatidyl choline 2g
Cholesterol 0.5g
Cholesterol sulfate sodium 0.005g
Vitamin E 0.025g
Sucrose 6.5g
Water for injection 75ml
The paclitaxel, dipalmitoyl phosphatidyl choline, cholesterol, the cholesterol sulfate sodium vitamin E that take by weighing recipe quantity respectively add the 100ml dehydrated alcohol, after the dissolving, prepare film forming with Rotary Evaporators, put the placement of spending the night in the vacuum desiccator, remove residual solvent.Adding is with the dissolved sucrose solution of water for injection, 58 ℃ of water-baths, and magnetic agitation 1 hour, ultra-sonic dispersion adopts 0.8,0.4,0.2 micrometer polycarbonate film successively, extrudes with the extruder high pressure, divides the cillin bottle of packing into, lyophilization, gland seal.
Method is measured similarly to Example 1, and the mean diameter of sample is 138.6 nanometers before the lyophilizing, and envelop rate is 86.4%.
The preparation of embodiment 6 Paclitaxel liposomes
Prescription
Paclitaxel 0.15g
Hydrolecithin 4g
Cholesterol 0.4g
Cholesterol sulfate potassium 0.001g
Sucrose 35g
Water for injection 200ml
The paclitaxel, hydrolecithin, cholesterol, the cholesterol sulfate potassium that take by weighing recipe quantity respectively add the 100ml dehydrated alcohol, after the dissolving, prepare film forming with Rotary Evaporators, put the placement of spending the night in the vacuum desiccator, remove residual solvent.Adding is with the dissolved sucrose solution of water for injection, 55 ℃ of water-baths, magnetic agitation 1 hour, ultra-sonic dispersion, use the high pressure homogenizer homogenizing, extrude with 0.2 micrometer polycarbonate film, 0.22 micron pvdf membrane aseptic filtration divides the cillin bottle of packing into, lyophilization passes to argon, gland seal in the cillin bottle.
Method is measured similarly to Example 1, and the mean diameter of sample is 178.5 nanometers before the lyophilizing, and envelop rate is 92.4%.
The stability test of embodiment 7 Paclitaxel liposome compositionss
This test is intended to investigate the bin stability and the stability in use of the liposomal samples for preparing among the embodiment.
The exsiccant Paclitaxel liposome compositions that makes among the embodiment 1,2,3 is stored 2～10 ℃ of long-term stabilities, observe its outward appearance, after redissolving with water for injection,, the results are shown in Table 1 with microscopic examination; Put 12 hours this solution chamber is gentle, regularly observe, the results are shown in Table 2.By the result as can be known, the taxusol-lipid thin film, is not assembled after the redissolution after 12 months 2～10 ℃ of storages, and no paclitaxel crystallization is separated out; Placed 12 hours after redissolving, do not assemble, no paclitaxel crystallization is separated out.
Table 1 taxusol-lipid body hypothermia (2-10 ℃) shelf-stability result of the test
Room temperature shelf-stability result of the test after table 2 Paclitaxel liposome redissolves
The acute toxicity test of embodiment 8 Paclitaxel liposomes
This embodiment is intended to investigate Paclitaxel liposome of the present invention instant toxic reaction after the administration and the toleration of multiple dosing in the usual way.
The Paclitaxel liposome of preparation among the embodiment 1 is redissolved with water for injection.Experimental animal: Kunming kind female mice, body weight 18～20g is divided into 4 groups at random, and 5 every group, negative group is given and the test group coordinative solvent of high volume.The 1st, 4,7 days to each the group with intravenous administration.
Result of the test: (1) instant toxicity is observed: each organizes immediate observation after the mice administration, no obvious toxicity.(2) mice body weight change: the mice body weight change is little after the administration of paclitaxel group, and the mice body weight has decline after the administration for the third time, and body weight progressively rises afterwards.Blank solvent group mice body weight progressively rises.
Concrete outcome sees Table 3.
The weight of animals changes in the acute toxicity test of table 3 Paclitaxel liposome
The test of embodiment 9 antitumor actions
Carry out preliminary antitumor test with the Paclitaxel liposome compositions of preparation among the embodiment 1.Laboratory animal adopts C
57BL/6 deceives mice, and is male, body weight 19～22g, random packet, 10 every group.Get B16 melanoma source, adopt the homogenate method, 1:6 is prepared into tumor cell suspension with normal saline, right axil subcutaneous vaccination B16 melanoma, and behind the tumor inoculation 24 hours, immediate reaction and body weight change were observed in the mouse tail vein injection administration.After experiment finishes, cut open and get tumor and weigh, be calculated as follows tumor control rate.
The average tumor of the average tumor weight-administration of tumor control rate %=[(matched group group is heavy)/the average tumor of matched group is heavy] * 100%
Result of the test: (1) immediate reaction is observed: Paclitaxel liposome does not have the reaction of instant obviously side effect after respectively organizing administration.After taxol is respectively organized the mouse vein administration (annotating speed is 1 ml/min), instant mice is the semicoma state, can recover gradually about 15 minutes.(2) each treated animal body weight has no significant change.(3) under the situation that accumulated dose equates, the tumor killing effect no significant difference of Paclitaxel liposome and taxol (seeing Table 4).
Table 4 Paclitaxel liposome different dosing regimes is to murine melanoma B16 (subcutaneous vaccination) clinical trial
Claims (10)
1. a stabilized liposomes is characterized in that, the one-tenth membrane lipid of liposome comprises 3 substitutive derivatives of hydrogenation saturated phospholipid, cholesterol and cholesterol, and active component is wrapped in the liposome; 3 substitutive derivatives of described cholesterol are selected from cholesterol sulfate sodium salt or cholesterol sulfate potassium salt; Described active component is a paclitaxel; The carbon number that described hydrogenation saturated phospholipid is selected from the saturated fat acidic group is 14～18 hydrogenation saturated phospholipid, and the molar ratio of hydrogenation saturated phospholipid, cholesterol, cholesterol sulfate sodium salt or potassium salt is: 100:20-50:0.2-5.
2. liposome as claimed in claim 1 is characterized in that, described hydrogenation saturated phospholipid is selected from the saturated soybean phospholipid of hydrogenation, the saturated lecithin of hydrogenation, dipalmitoyl phosphatidyl choline, distearoyl phosphatidylcholine.
3. liposome as claimed in claim 1 is characterized in that, the molar ratio of described hydrogenation saturated phospholipid, cholesterol, cholesterol sulfate sodium salt or potassium salt is: 100:35-45:0.5-2.
4. liposome as claimed in claim 1 is characterized in that, described liposome composition further comprises natural type or synthesising complex E as antioxidant, and the weight ratio of itself and hydrogenation saturated phospholipid is 0.3-1:100.
5. liposome as claimed in claim 1 is characterized in that, the molar ratio of described paclitaxel and hydrogenation saturated phospholipid is: 2-8:100.
6. liposome as claimed in claim 1 is characterized in that, the mean diameter of liposome is in 100 nanometer to 300 nanometer range.
7. a compositions that comprises the arbitrary described liposome of claim 1 to 6 is characterized in that, said composition further comprises the lyophilizing protective agent, and its dosage form is a lyophilized preparation.
8. liposome composition as claimed in claim 7 is characterized in that, described lyophilizing protective agent is selected from sucrose, lactose, maltose, glucose.
9. liposome composition as claimed in claim 8 is characterized in that, described lyophilizing protective agent is 2-10 a times of hydrogenation saturated phospholipid weight.
10. the arbitrary described liposome composition of claim 7 to 9 is in the purposes of preparation aspect the cancer therapy drug, and wherein the cancer kind is ovarian cancer, metastatic carcinoma of ovary, breast carcinoma, nonsmall-cell lung cancer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101487072A CN100496609C (en) | 2006-12-30 | 2006-12-30 | Stable liposome composition |
| PCT/CN2008/000014 WO2008080369A1 (en) | 2006-12-30 | 2008-01-02 | Steady liposomal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101487072A CN100496609C (en) | 2006-12-30 | 2006-12-30 | Stable liposome composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101002733A CN101002733A (en) | 2007-07-25 |
| CN100496609C true CN100496609C (en) | 2009-06-10 |
Family
ID=38702262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101487072A Active CN100496609C (en) | 2006-12-30 | 2006-12-30 | Stable liposome composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN100496609C (en) |
| WO (1) | WO2008080369A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584663B (en) * | 2008-05-22 | 2013-02-20 | 广州瑞济生物技术有限公司 | Novel delivery system of Duoxitasai lipidosome for injection and preparation method thereof |
| RU2538199C2 (en) * | 2009-02-04 | 2015-01-10 | Дзе Бригхэм Энд Вимен'З Хоспитэл, Инк. | Platinum nanocompounds and methods of applying thereof |
| CN101642255B (en) * | 2009-07-31 | 2012-05-23 | 东北农业大学 | Method for embedding docosahexaenic acid by thin film evaporation-freeze drying |
| CN101797264B (en) * | 2010-03-23 | 2012-05-30 | 广州朗圣药业有限公司 | Amphotericin B lipid complex for injection and preparation method thereof |
| CN101889982B (en) * | 2010-04-15 | 2012-12-26 | 山东京卫制药有限公司 | Novel long-circulating liposome composition and preparation method thereof |
| PT3138555T (en) | 2014-04-30 | 2020-12-15 | Fujifilm Corp | Liposome composition and production method therefor |
| HK1252369A1 (en) * | 2015-02-13 | 2019-05-24 | 友杏生技医药股份有限公司 | Compositions and methods of tumor treatment utilizing nanoparticles |
| CN111437259A (en) * | 2015-11-02 | 2020-07-24 | 富士胶片株式会社 | Liposome composition comprising gemcitabine or a salt thereof |
| JP7364561B2 (en) | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | Combination drug containing a liposome composition containing gemcitabine and an immune checkpoint inhibitor |
| IT201900019775A1 (en) * | 2019-10-25 | 2021-04-25 | Health Progress Italia S R L | LIPOSOMIAL NUTRACEUTICAL COMPOSITION |
| CN116196283A (en) * | 2021-11-30 | 2023-06-02 | 深圳玖星制药有限公司 | Preparation method and raw material composition of taxane drug liposome freeze-dried powder for injection |
| CN115414491B (en) * | 2022-10-11 | 2025-05-06 | 青岛市肿瘤医院 | Medicine for treating cervical cancer and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0825869B2 (en) * | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | Antitumor agent-embedded liposome preparation |
-
2006
- 2006-12-30 CN CNB2006101487072A patent/CN100496609C/en active Active
-
2008
- 2008-01-02 WO PCT/CN2008/000014 patent/WO2008080369A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| 载药脂质体物理化学稳定性的研究进展. 蔡明志等.国外医学药学分册，第32卷第6期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008080369A1 (en) | 2008-07-10 |
| CN101002733A (en) | 2007-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100496609C (en) | Stable liposome composition | |
| CN111973557B (en) | Docetaxel liposome, preparation method and application thereof | |
| CN101889982B (en) | Novel long-circulating liposome composition and preparation method thereof | |
| Zhang et al. | Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice | |
| JP2009507049A (en) | Nanomicelle formulation of vinca alkaloid anticancer drug encapsulated in polyethylene glycol derivative of phospholipid | |
| CN105853403B (en) | A kind of paclitaxel palmitate liposome and preparation method thereof | |
| CN107149592B (en) | Biological self-assembly nano-crystalline injection and preparation method with lympha targeted function | |
| CN105708847B (en) | Ginsenoside multicomponent carries the preparation method and applications of targeted nano system altogether | |
| CN105456194A (en) | Magnolol liposome and derivative preparation and preparation method thereof | |
| CN103720658A (en) | Heparin-modified adriamycin liposome preparation and preparation method thereof | |
| CN102302447B (en) | Novel taxol lipid microsphere injection and preparation method thereof | |
| CN107753429A (en) | A kind of preparation of Norcantharidin Liver targeting liposome and its application of lyophilized formulations | |
| Song et al. | TPGS-modified long-circulating liposomes loading ziyuglycoside I for enhanced therapy of myelosuppression | |
| CN103989624B (en) | A kind of irinotecan hydrochloride composition and preparation method thereof | |
| CN101028251A (en) | Camptothecine derivative phosphatide composite liposome nano-preparation and its making method | |
| CN103006546A (en) | Preparation and application of carbon nano tube-containing thermo-sensitive type gel entrapping for indissolvable drug | |
| CN102716089B (en) | Gemcitabine hydrochloride liposome injection | |
| CN104324007B (en) | Preparation technology and application of natural recombinant nanostructured lipid carrier | |
| CN101322681B (en) | A kind of method for preparing the nano micellar preparation of anthracycline antitumor antibiotic | |
| CN102670525A (en) | Application of ursolic-acid nano medicine-carrying microspheres for treating tumors and preparation | |
| CN105919935B (en) | Sorafenib medicine lipid nano suspension and preparation method thereof | |
| CN102085189B (en) | Docetaxel liposome sterile lyophilized preparation and preparation method thereof | |
| CN113384705A (en) | Preparation of poloxamer modified liposome and application of poloxamer modified liposome in oral drug delivery | |
| CN102552149B (en) | Calcium heparin liposome preparation for injection | |
| CN105232460A (en) | Preparation and application of oxaliplatin lipidosome freeze-dried powder injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201210, Zhangjiang hi tech park, Shanghai, Harley Road, No. 5, building 1118 Patentee after: Shanghai ALLIST medicine Polytron Technologies Inc. Address before: 201210, Zhangjiang hi tech park, Shanghai, Harley Road, No. 5, building 1118 Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 201203 floor 5, building 1, No. 1118, Halley Road, No. 1227, zhangheng Road, Shanghai pilot Free Trade Zone Patentee after: Shanghai ALLIST medicine Polytron Technologies Inc. Address before: 201210, Zhangjiang hi tech park, Shanghai, Harley Road, No. 5, building 1118 Patentee before: Shanghai ALLIST medicine Polytron Technologies Inc. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai, 201318 Patentee after: Shanghai ALLIST medicine Polytron Technologies Inc. Address before: 5 / F, building 1, 1118 Harley Road, 1227 zhangheng Road, Shanghai pilot Free Trade Zone, 201203 Patentee before: Shanghai ALLIST medicine Polytron Technologies Inc. |
|
| CP02 | Change in the address of a patent holder |